



Pixium Vision implants additional patients in the European clinical trial of its epi-retinal system IRIS®

Paris, France - October 21, 2015 –Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced today the implantation of 3 patients since July in the clinical trial of IRIS®, the company's first Vision Restoration System.

Dr. Yannick Le Mer, ophthalmic surgeon at the Rothschild Foundation Hospital in Paris, commented: *"The three surgeries realized in Europe since July were successfully completed. Following the usual post-operative observation period, patients are followed up for 18 months, per clinical protocol."*

IRIS® Vision Restoration System is intended for patients who have lost their sight due to retinitis pigmentosa, a genetic disease causing degeneration of photoreceptors.

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision's VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. Pixium Vision plans to file IRIS's CE mark dossier before the end of 2015 and expects to launch IRIS® during the first half of 2016.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

The company is ISO 13485 certified.

Contacts

Pixium Vision

Pierre Kemula, CFO

investors@pixium-vision.com

+33 1 76 21 47 30

 @PixiumVision

Relations Presse

Newcap Media

Annie-Florence Loyer

afloyer@newcap.fr – 06 88 20 35 59

Daphné Boccara

dboccara@newcap.fr – 01 44 71 0012



Pixium Vision is listed on Euronext (Compartment C) in Paris.

ISIN: FR0011950641; Mnemo: PIX

IRIS® is a trademark of Pixium-Vision SA

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R15-069 on September 23, 2015 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).